Free Newsletter
Salk researchers unveil breakthrough on genetic diseases
Researchers at the Salk Institute for Biological Studies in La Jolla, CA, have combined stem cell and gene therapy techniques into a new approach that could point the way to a cure for some of the world's most devastating ailments.
Their research project involved taking a defective cell from patients suffering from Fanconi anemia--a genetic disease that can trigger leukemia and other fatal diseases--and correcting the defective gene that causes the condition. The repaired cells were then made into induced pluripotent stem cells, or iPS cells, which readily differentiated into hematopoietic progenitor cells primed to differentiate into healthy blood cells.
"We haven't cured a human being, but we have cured a cell," says the study's leader, Juan-Carlos Izpisúa Belmonte. "In theory we could transplant it into a human and cure the disease."
"If we can demonstrate that a combined iPS-gene therapy approach works in humans, then there is no limit to what we can do," says Inder Verma, who worked on the project.
- check out the press release
Related Articles:
Salk president calls for more research spending
Ipsen, Salk Institute ink research pact
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession





SHARE
WITH: